Partial Nephrectomy for Patients with Severe Chronic Kidney Disease-Is It Worthwhile?


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 19 3 2020
medline: 22 10 2020
entrez: 19 3 2020
Statut: ppublish

Résumé

Partial nephrectomy is prioritized over radical nephrectomy in patients with chronic kidney disease whenever feasible. However, we hypothesized that some patients with severe chronic kidney disease might rapidly progress to end stage renal disease, in which case the morbidity that can be associated with partial nephrectomy would not be justified. A retrospective review of all 62 patients with stage IV chronic kidney disease undergoing partial nephrectomy at our institution (1999-2015) was performed. We analyzed preoperative/intraoperative factors and postoperative outcomes. Survival-analyses evaluated factors associated with time-to-progression to end stage renal disease the primary end point. Median age was 67 years, 71% of patients were male, and 84% Caucasian. Comorbidities included hypertension (94%), cardiovascular disease (53%) and diabetes (32%). Median preoperative estimated glomerular filtration rate was 23 ml/minute/1.73 m Our data suggest that some patients with stage IV chronic kidney disease undergoing partial nephrectomy have substantial comorbidities and nonaggressive pathology, and are at risk for unfavorable perioperative outcomes and rapid-progression to end stage renal disease. Renal mass biopsy should be strongly considered to improve patient-selection. Alternate strategies (active surveillance or radical nephrectomy) may be more appropriate, particularly when partial nephrectomy is high complexity or when the patient is African American, or preoperative glomerular filtration rate is less than 25 ml/minute/1.73 m

Identifiants

pubmed: 32186436
doi: 10.1097/JU.0000000000001021
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

434-441

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Diego Aguilar Palacios (D)

Glickman Urological and Kidney Institute-Cleveland Clinic Foundation, Cleveland, Ohio.

Jianbo Li (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.

Furman Mahmood (F)

Glickman Urological and Kidney Institute-Cleveland Clinic Foundation, Cleveland, Ohio.

Sevag Demirjian (S)

Glickman Urological and Kidney Institute-Cleveland Clinic Foundation, Cleveland, Ohio.

Robert Abouassaly (R)

Glickman Urological and Kidney Institute-Cleveland Clinic Foundation, Cleveland, Ohio.

Steven C Campbell (SC)

Glickman Urological and Kidney Institute-Cleveland Clinic Foundation, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH